Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$BSX Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.73 down -2.67% YoY • Reported revenue of $5.14B up 1.44% YoY • Boston Scientific estimates FY2026 reported and organic sales growth of approximately 4.25% and 3.75%, with adjusted EPS $3.16 to $3.18; Q4 reported and organic sales decline (3.0)% to (1.0)%, with adjusted EPS $0.77 to $0.79.

Price since post

Full Details

Advertisement|Remove ads.